KAYS
Kaya Holdings, Inc.
Key Financials
Gross Profit
$-366
↓ 100.3%
Revenue
$7134
↓ 96.4%
Operating Income
$-2022028
↓ 62.5%
Total Liabilities
$17.3M
↑ 8.6%
Total Assets
$216369.00
↑ 0.2%
EPS (Diluted)
$-0.07
↓ 800.0%
Net Income
$-2080856
↓ 229.3%
Cash & Equivalents
$29108.00
↑ 58.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| NT 10-K | 3/30/2026 | View on SEC |
| 8-K | 11/28/2025 | View on SEC |
| 10-Q | 11/20/2025 | View on SEC |
| NT 10-Q | 11/13/2025 | View on SEC |
| 8-K | 10/23/2025 | View on SEC |
| 8-K | 9/22/2025 | View on SEC |
| 10-Q | 8/27/2025 | View on SEC |
| NT 10-Q | 8/13/2025 | View on SEC |
| 10-Q | 5/21/2025 | View on SEC |
| 10-K/A | 5/19/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KAYS |
| Company Name | Kaya Holdings, Inc. |
| CIK | 1530746 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 954-5347895 |